Catalyst Brief

← Calendar

Readoutin 14d

Viatris Innovation GmbH — Cenerimod

Phase 3 primary completion: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus.

Date
Dec 2026
Type
Readout
Indication
Lupus Erythematosus, Systemic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Viatris Innovation GmbH

  1. Mar2027